This small biotech with an already approved drug for cataract surgery in the market and being used by leading teaching hospitals associated with Harvard and Columbia, to just name a couple. Revenue from this drug will increase gradually particularly with all those residents and fellows trained at these leading hospitals, who will adopt it in their post training practices. This alone should warrant a huge price tag for the shares. Then they also have a couple drugs in development with solid results reported recently. OMER is among a very few biotechs with such portfolio of drug and potential drugs already. Keep your shares for big payday and ignore its daily movement. The lone analyst came out after the CC with a downgrade provided opportunities for investors who know better. This guy is either ignorant or tries to manipulate for his firm's short position. Who cares. OMER is among the best investment in this sector with multifold gains for those with patience.
This stock acts as if something big may happen soon. Whenever it went down some due to profit taking, it then moved back up immediately without any news accounting for the upward move. Wonder if something cooking behind the scene. In any case this one will do very well in the long term. I will not trade it for small gain to miss the boat.
Regarding EU partnership for Omidria: positive review out of EU from 9/16 indicates high probability of partnership/distribution agreement for European countries:
Patient Prefer Adherence. 2016 Sep 15;10:1795-1801. eCollection 2016. Patient considerations in cataract surgery - the role of combined therapy using phenylephrine and ketorolac.
Gonzalez-Salinas R1, Guarnieri A2, Guirao Navarro MC2, Saenz-de-Viteri M2. Author information 1 Department of Biomedical Research, Universidad Autónoma de Querétaro, Querétaro, Mexico; Department of Research, Asociación para Evitar la Ceguera en México, Mexico City, Mexico. 2 Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain. Abstract Cataract, a degradation of the optical quality of the crystalline lens, progressive and age-related, is the leading cause of treatable blindness worldwide. Cataract surgery is the most common surgical procedure performed by ophthalmologists and is the only effective treatment for cataracts. Advances in the surgical techniques and better postoperative visual outcomes have progressively changed the primary concern of cataract surgery to become a procedure refined to yield the best possible refractive results. Sufficient mydriasis during cataract removal is critical to a successful surgical outcome. Poor pupil dilation can lead to serious sight-threatening complications that significantly increase the cost of surgery and decrease patients comfort. Mydriasis is obtained using anticholinergic and sympathomimetic drugs. Phenylephrine, an α1-adrenergic receptor agonist, can efficiently dilate the pupil when administered by intracameral injection. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) like ketorolac, which inhibit the synthesis of prostaglandins, are used to decrease intraoperative miosis, control pain and inflammation associated with cataract surgery, and to prevent the development of cystoid macular edema following surgery. Recently, a new combination of phenylephrine and ketorolac (Omidria®) has been approved by United States Food and Drug Administration for use during cataract surgery to maintain intraoperative mydriasis, prevent miosis, and reduce postoperative pain and inflammation. Clinical trials have shown that this new combination is effective, combining the positive effects of both drugs with a good safety profile and patient tolerability. Moreover, recent reports suggest that this combination is also effective in patients with high risk of poor pupil dilation. In conclusion, cataract is a global problem that significantly affects patients' quality of life. However, they can be managed with a safe and minimally invasive surgery. Advances in surgical techniques and newer pharmacological agents such as the combination of phenylephrine and ketorolac, together with better intraocular lenses, have greatly improved visual outcomes and thus patients' expectations regarding visual recovery are also increasing.
[Full text] Patient considerations in cataract surgery - the role of combine | PPA
Patient considerations in cataract surgery â�� the role of combined therapy using phenylephrine and ketorolac Roberto Gonzalez-Salinas,1,2 Adriano Guarnieri,3 MarÃa ConcepciÃ³n Guirao Navarro,3 Manuel Saenz-de-Viteri3 1Department of Biomedical Rese
I have a feeling we're going to be hearing "big news, any day now" for a long time.....
Former OMER Stock Promoter BadDay, now Sell Out OMER Stock Promoter BadDay, is taking a bath on his RAD stock position. You know, he switched to RAD Stock Promoter BadDay and spammed our board.
He is calling for investors to contact IR at RAD. Cry baby blew it again. Sold OMER and took his $2 a share profit and sunk it into RAD over $6! Now he is begging for buyers all over the place.
Serves you right RAD Stock Promoter BadDay for pumping and spamming. Bad karma dude. Stay on topic on relevant boards to stocks spammer!
i've had a buy order in the last 2 days for 15.65 but absolutely refuses to drop it to that level. oh well, at least im already heavily loaded up.
Classic OMER...every early morning pop on no news, followed by falling off a cliff just to finish the day below the open
Hey RAD Stock Promoter BadDay, I made comments to your posts over there for today. You did not delete all of your posts. It looks like others have noticed that you delete your pumps at RAD kinda like you did at OMER. Go check it out. Maybe you wasted a day, delete, delete, delete..... SS SensiSEATTLE
Short Interest updated today after the close as of May 15.
Seriously overpriced at $16+. $750,000,000 for P2 data is insanity.There are lots of slips between the cup and lips.Many drugs have stellar P2 results, only to falter in P3.Paying 3/4 of $billion now for a #$%$ shoot years from now is TulipMania.
At least some are raking it in here. 2016 compensation: Demopukus ..... $6,380,956 Jacobscum ..... $1,526,041 Kelbutt ............ $1,535,148 The insiders are filling their pockets and emptying the shareholders'.
The Duke (or is it The Dupe?), how is Rite Aid working out for you and GreatLoserIsBack2017? Down an additional 8%+ today. LOLOLOLOLOLOL
Nice early movement, but with the low volume, I doubt it lasts long.
Who got conned into paying over $17 this morning for a $9 bag?
You watch now posters. RAD Stock Promoter BadDay muted me. Now he will post here and after not seeing my comments for a month he will change his alias. He does not like comments he cannot see and he knows not how to take someone off mute.
It will be a Trainwreck.
$17.13 for a triple top and now down we go. A stampede out the door!